Dept. of Hematology, Karolinska University Hospital
Stockholm, SE-171 76, Sweden
Completed
NCT Number: NCT00162851
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–80 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- B-CLL that has failed fludarabine
Exclusion criteria
- Performance status grade 3
Treatment and study plan
Alemtuzumab
DrugSponsors and collaborators
Lead sponsor
Karolinska University Hospital
Other
Collaborators
- Schering Nordiska AB
Registry information
Official study title
A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia
Important dates
- Study start
- 2003
- Study completion
- 2006
- First posted
- Sep 13, 2005
- Registry last updated
- Jul 25, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.